View Additional Topics:
Special Topics: Interstitial Lung Disease/Pulmonary Fibrosis (ILD/IPF)
-
Sponsored Content
A Landmark Moment: A Discussion on JASCAYD® (nerandomilast) tablets
on
Read more: A Landmark Moment: A Discussion on JASCAYD® (nerandomilast) tabletsPlease join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium where they will provide a comprehensive review of JASCAYD® (nerandomilast) tablets. During this event, Dr. Hamblin and Dr. Scholand will discuss the safety and efficacy data of JASCAYD,…
-
ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPF
on
Read more: ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPFThe ATS 2026 International Conference will spotlight a wide range of recent investigative and clinical advances in the treatment of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), including the development of nerandomilast, the first FDA-approved therapy for IPF in over a decade. Susan K. Mathai, MD, spoke with ATS Conference News to preview…
-
ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD Treatments
on
Read more: ATS 2026 Orlando Spotlights Recent Advancements in Pediatric ILD TreatmentsTreating pediatric patients with ILD or IPF can require unique treatment considerations and innovations compared with the treatment of adult populations. The relative rarity of pediatric patients with ILD reveals an urgent need for education among pediatric subspecialty providers and primary care physicians about how to diagnose and treat these diseases in collaboration with pediatric…
-
ILD and IPF Lineup at ATS 2026 Orlando
on
Read more: ILD and IPF Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating ILD and IPF.